U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
Cosyntropin (ACTH (1–24)) is a synthetic peptide that is identical to the 24-amino acid segment at the N-terminal of adrenocorticotropic hormone. It is intended for use as a diagnostic agent in the screening of patients presumed to have adrenocortical insufficiency. Cosyntropin may bind to sites located on the adrenergic nerve endings associated with the cardiac tissue, and such binding would interfere with the neuronal reuptake of the catecholamines

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: Q01718
Gene ID: 4158.0
Gene Symbol: MC2R
Target Organism: Homo sapiens (Human)
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Diagnostic
CORTROSYN

Approved Use

Cortrosyn™ (cosyntropin) for Injection is intended for use as a diagnostic agent in the screening of patients presumed to have adrenocortical insufficiency. Because of its rapid effect on the adrenal cortex it may be utilized to perform a 30-minute test of adrenal function (plasma cortisol response) as an office or outpatient procedure, using only 2 venipunctures (seeDOSAGE AND ADMINISTRATION section). Severe hypofunction of the pituitary - adrenal axis is usually associated with subnormal plasma cortisol values but a low basal level is not per se evidence of adrenal insufficiency and does not suffice to make the diagnosis. Many patients with proven insufficiency will have normal basal levels and will develop signs of insufficiency only when stressed. For this reason a criterion which should be used in establishing the diagnosis is the failure to respond to adequate corticotropin stimulation. When presumptive adrenal insufficiency is diagnosed by a subnormal Cortrosyn™ test, further studies are indicated to determine if it is primary or secondary. Primary adrenal insufficiency (Addison's disease) is the result of an intrinsic disease process, such as tuberculosis within the gland. The production of adrenocortical hormones is deficient despite high ACTH levels (feedback mechanism). Secondary or relative insufficiency arises as the result of defective production of ACTH leading in turn to disuse atrophy of the adrenal cortex. It is commonly seen, for example, as result of corticosteroid therapy, Sheehan's syndrome and pituitary tumors or ablation. The differentiation of both types is based on the premise that a primarily defective gland cannot be stimulated by ACTH whereas a secondarily defective gland is potentially functional and will respond to adequate stimulation with ACTH. Patients selected for further study as the result of a subnormal Cortrosyn™ test should be given a 3 or 4 day course of treatment with Repository Corticotropin Injection USP and then retested. Suggested doses are 40 USP units twice daily for 4 days or 60 USP units twice daily for 3 days. Under these conditions little or no increase in plasma cortisol levels will be seen in Addison's disease whereas higher or even normal levels will be seen in cases with secondary adrenal insufficiency.

Launch Date

9.504E9
PubMed

PubMed

TitleDatePubMed
Adrenocorticotropin binding sites in rat cardiac tissue.
1990 Jan
Stress-related gene expression in brain and adrenal gland of porcine fetuses and neonates.
2005 Mar 1
Subtyping of primary aldosteronism with adrenal vein sampling: Hormone- and side-specific effects of cosyntropin and metoclopramide.
2018 Apr

Sample Use Guides

Cortrosyn™ (cosyntropin) for Injection may be administered intramuscularly or as a direct intravenous injection when used as a rapid screening test of adrenal function. It may also be given as an intravenous infusion over a 4 to 8 hour period to provide a greater stimulus to the adrenal glands. Doses of Cortrosyn™ 0.25 to 0.75 mg have been used in clinical studies and a maximal response noted with the smallest dose.
Route of Administration: Other
Name Type Language
COSYNTROPIN
HSDB   MI   ORANGE BOOK   USAN   VANDF  
USAN  
Official Name English
TETRACOSACTIDE
EP   INN   MART.   WHO-DD  
INN  
Official Name English
TETRACOSACTIDE [MART.]
Common Name English
Tetracosactide [WHO-DD]
Common Name English
COSYNTROPIN [USAN]
Common Name English
ADRENOCORTICOTROPIC HORMONE FRAGMENT 1-24 HUMAN, RAT
Common Name English
TETRACOSACTIDE [EP MONOGRAPH]
Common Name English
CORTICOTROPIN TETRACOSAPEPTIDE
Common Name English
VICOTROPE
Brand Name English
COSYNTROPIN [ORANGE BOOK]
Common Name English
COSYNTROPIN [USP MONOGRAPH]
Common Name English
SER-TYR-SER-MET-GLU-HIS-PHE-ARG-TRP-GLY-LYS-PRO-VAL-GLY-LYS-LYS-ARG-ARG-PRO-VAL-LYS-VAL-TYR-PRO
Common Name English
COSYNTROPIN [VANDF]
Common Name English
L-SERYL-L-TYROSYL-L-SERYL-L-METHIONYL-L-GLUTAMYL-L-HISTIDYL-L-PHENYLALANYL-L-ARGINYL-L-TRYPTOPHYLGLYCYL-L-LYSYL-L-PROLYL-L-VALYLGLYCYL-L-LYSYL-L-LYSYL-L-ARGINYL-L-ARGINYL-L-PROLYL-L-VALYL-L-LYSYL-L-VALYL-L-TYROSYL-L-PROLINE
Common Name English
TETRACOSACTRIN
Common Name English
tetracosactide [INN]
Common Name English
COSYNTROPIN [MI]
Common Name English
COSYNTROPIN [HSDB]
Common Name English
CORTROSYN
Brand Name English
Classification Tree Code System Code
NDF-RT N0000006478
Created by admin on Sat Dec 16 00:25:59 UTC 2023 , Edited by admin on Sat Dec 16 00:25:59 UTC 2023
EU-Orphan Drug EU/3/18/2054
Created by admin on Sat Dec 16 00:25:59 UTC 2023 , Edited by admin on Sat Dec 16 00:25:59 UTC 2023
NDF-RT N0000006478
Created by admin on Sat Dec 16 00:25:59 UTC 2023 , Edited by admin on Sat Dec 16 00:25:59 UTC 2023
NDF-RT N0000006478
Created by admin on Sat Dec 16 00:25:59 UTC 2023 , Edited by admin on Sat Dec 16 00:25:59 UTC 2023
FDA ORPHAN DRUG 594017
Created by admin on Sat Dec 16 00:25:59 UTC 2023 , Edited by admin on Sat Dec 16 00:25:59 UTC 2023
NCI_THESAURUS C1937
Created by admin on Sat Dec 16 00:25:59 UTC 2023 , Edited by admin on Sat Dec 16 00:25:59 UTC 2023
FDA ORPHAN DRUG 609817
Created by admin on Sat Dec 16 00:25:59 UTC 2023 , Edited by admin on Sat Dec 16 00:25:59 UTC 2023
NDF-RT N0000006478
Created by admin on Sat Dec 16 00:25:59 UTC 2023 , Edited by admin on Sat Dec 16 00:25:59 UTC 2023
WHO-ATC H01AA02
Created by admin on Sat Dec 16 00:25:59 UTC 2023 , Edited by admin on Sat Dec 16 00:25:59 UTC 2023
NDF-RT N0000006478
Created by admin on Sat Dec 16 00:25:59 UTC 2023 , Edited by admin on Sat Dec 16 00:25:59 UTC 2023
FDA ORPHAN DRUG 545216
Created by admin on Sat Dec 16 00:25:59 UTC 2023 , Edited by admin on Sat Dec 16 00:25:59 UTC 2023
NDF-RT N0000006478
Created by admin on Sat Dec 16 00:25:59 UTC 2023 , Edited by admin on Sat Dec 16 00:25:59 UTC 2023
WHO-VATC QH01AA02
Created by admin on Sat Dec 16 00:25:59 UTC 2023 , Edited by admin on Sat Dec 16 00:25:59 UTC 2023
NDF-RT N0000006478
Created by admin on Sat Dec 16 00:25:59 UTC 2023 , Edited by admin on Sat Dec 16 00:25:59 UTC 2023
NDF-RT N0000175941
Created by admin on Sat Dec 16 00:25:59 UTC 2023 , Edited by admin on Sat Dec 16 00:25:59 UTC 2023
Code System Code Type Description
HSDB
3307
Created by admin on Sat Dec 16 00:25:59 UTC 2023 , Edited by admin on Sat Dec 16 00:25:59 UTC 2023
PRIMARY
NCI_THESAURUS
C28941
Created by admin on Sat Dec 16 00:25:59 UTC 2023 , Edited by admin on Sat Dec 16 00:25:59 UTC 2023
PRIMARY
CHEBI
3901
Created by admin on Sat Dec 16 00:25:59 UTC 2023 , Edited by admin on Sat Dec 16 00:25:59 UTC 2023
PRIMARY
ChEMBL
CHEMBL2103784
Created by admin on Sat Dec 16 00:25:59 UTC 2023 , Edited by admin on Sat Dec 16 00:25:59 UTC 2023
PRIMARY
WIKIPEDIA
TETRACOSACTIDE
Created by admin on Sat Dec 16 00:25:59 UTC 2023 , Edited by admin on Sat Dec 16 00:25:59 UTC 2023
PRIMARY
INN
2255
Created by admin on Sat Dec 16 00:25:59 UTC 2023 , Edited by admin on Sat Dec 16 00:25:59 UTC 2023
PRIMARY
RXCUI
2890
Created by admin on Sat Dec 16 00:25:59 UTC 2023 , Edited by admin on Sat Dec 16 00:25:59 UTC 2023
PRIMARY RxNorm
MERCK INDEX
m3809
Created by admin on Sat Dec 16 00:25:59 UTC 2023 , Edited by admin on Sat Dec 16 00:25:59 UTC 2023
PRIMARY Merck Index
CAS
16960-16-0
Created by admin on Sat Dec 16 00:25:59 UTC 2023 , Edited by admin on Sat Dec 16 00:25:59 UTC 2023
PRIMARY
WIKIPEDIA
Adrenocorticotropic hormone (medication)
Created by admin on Sat Dec 16 00:25:59 UTC 2023 , Edited by admin on Sat Dec 16 00:25:59 UTC 2023
PRIMARY
PUBCHEM
16133751
Created by admin on Sat Dec 16 00:25:59 UTC 2023 , Edited by admin on Sat Dec 16 00:25:59 UTC 2023
PRIMARY
DRUG CENTRAL
4516
Created by admin on Sat Dec 16 00:25:59 UTC 2023 , Edited by admin on Sat Dec 16 00:25:59 UTC 2023
PRIMARY
FDA UNII
72YY86EA29
Created by admin on Sat Dec 16 00:25:59 UTC 2023 , Edited by admin on Sat Dec 16 00:25:59 UTC 2023
PRIMARY
DAILYMED
72YY86EA29
Created by admin on Sat Dec 16 00:25:59 UTC 2023 , Edited by admin on Sat Dec 16 00:25:59 UTC 2023
PRIMARY
SMS_ID
100000085201
Created by admin on Sat Dec 16 00:25:59 UTC 2023 , Edited by admin on Sat Dec 16 00:25:59 UTC 2023
PRIMARY
IUPHAR
6965
Created by admin on Sat Dec 16 00:25:59 UTC 2023 , Edited by admin on Sat Dec 16 00:25:59 UTC 2023
PRIMARY
EPA CompTox
DTXSID201014470
Created by admin on Sat Dec 16 00:25:59 UTC 2023 , Edited by admin on Sat Dec 16 00:25:59 UTC 2023
PRIMARY
MESH
D003366
Created by admin on Sat Dec 16 00:25:59 UTC 2023 , Edited by admin on Sat Dec 16 00:25:59 UTC 2023
PRIMARY
ECHA (EC/EINECS)
241-031-1
Created by admin on Sat Dec 16 00:25:59 UTC 2023 , Edited by admin on Sat Dec 16 00:25:59 UTC 2023
PRIMARY
EVMPD
SUB10941MIG
Created by admin on Sat Dec 16 00:25:59 UTC 2023 , Edited by admin on Sat Dec 16 00:25:59 UTC 2023
PRIMARY
DRUG BANK
DB01284
Created by admin on Sat Dec 16 00:25:59 UTC 2023 , Edited by admin on Sat Dec 16 00:25:59 UTC 2023
PRIMARY